Intrexon Stock Price, News & Analysis (NYSE:XON)

$12.84 -0.41 (-3.09 %)
(As of 02/21/2018 06:30 AM ET)
Previous Close$13.25
Today's Range$12.76 - $13.34
52-Week Range$10.26 - $26.99
Volume858,100 shs
Average Volume2.14 million shs
Market Capitalization$1.63 billion
P/E Ratio-11.46
Dividend YieldN/A
Beta1.4

About Intrexon (NYSE:XON)

Intrexon logoIntrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive XON News and Ratings via Email

Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:XON
CUSIPN/A
Phone+1-301-5569809

Debt

Debt-to-Equity Ratio0.01%
Current Ratio2.05%
Quick Ratio1.85%

Price-To-Earnings

Trailing P/E Ratio-11.4642857142857
Forward P/E Ratio-12.11
P/E GrowthN/A

Sales & Book Value

Annual Sales$190.93 million
Price / Sales8.58
Cash FlowN/A
Price / CashN/A
Book Value$4.80 per share
Price / Book2.68

Profitability

Trailing EPS($1.12)
Net Income$-186,610,000.00
Net Margins-66.88%
Return on Equity-18.68%
Return on Assets-11.34%

Miscellaneous

Employees935
Outstanding Shares127,520,000

Intrexon (NYSE:XON) Frequently Asked Questions

What is Intrexon's stock symbol?

Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."

How were Intrexon's earnings last quarter?

Intrexon Corp (NYSE:XON) issued its quarterly earnings results on Wednesday, May, 10th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.04. The biotechnology company earned $53.70 million during the quarter, compared to analysts' expectations of $49.08 million. Intrexon had a negative net margin of 66.88% and a negative return on equity of 18.68%. The company's quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.55) earnings per share. View Intrexon's Earnings History.

When will Intrexon make its next earnings announcement?

Intrexon is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Intrexon.

Where is Intrexon's stock going? Where will Intrexon's stock price be in 2018?

6 brokers have issued 1 year target prices for Intrexon's stock. Their predictions range from $21.00 to $57.00. On average, they anticipate Intrexon's stock price to reach $38.50 in the next year. View Analyst Ratings for Intrexon.

Who are some of Intrexon's key competitors?

Who are Intrexon's key executives?

Intrexon's management team includes the folowing people:

  • Randal J. Kirk, Chairman of the Board, Chief Executive Officer (Age 63)
  • Thomas D. Reed Ph.D., Founder, Chief Science Officer (Age 51)
  • Rick L. Sterling CPA, Chief Financial Officer (Age 53)
  • Thomas Bostick Ph.D., Chief Operating Officer
  • Joel Liffmann, Senior Vice President - Finance (Age 56)
  • Jack Anthony Bobo, Senior Vice President, Chief Communications Officer (Age 51)
  • Ena Chan Cratsenburg, Senior Vice President - Consumer Sector (Age 48)
  • Jeffrey T. Perez, Senior Vice President — Intellectual Property Affairs (Age 45)
  • Christopher Basta, Vice President - Investor Relations
  • Donald P. Lehr, Chief Legal Officer (Age 42)

Who owns Intrexon stock?

Intrexon's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include KIRK RANDAL J (45.70%), Third Security LLC (45.43%), KIRK RANDAL J (47.40%), Iridian Asset Management LLC CT (3.54%), BlackRock Inc. (2.01%) and First Trust Advisors LP (1.76%). Company insiders that own Intrexon stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Institutional Ownership Trends for Intrexon.

Who sold Intrexon stock? Who is selling Intrexon stock?

Intrexon's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Raymond James & Associates, TIAA CREF Investment Management LLC, LPL Financial LLC, Sanders Morris Harris LLC, Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Intrexon.

Who bought Intrexon stock? Who is buying Intrexon stock?

Intrexon's stock was purchased by a variety of institutional investors in the last quarter, including Third Security LLC, Iridian Asset Management LLC CT, First Trust Advisors LP, Two Sigma Investments LP, Frontier Capital Management Co. LLC, BlackRock Inc., First Washington CORP and Virtu Financial LLC. Company insiders that have bought Intrexon stock in the last two years include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Insider Buying and Selling for Intrexon.

How do I buy Intrexon stock?

Shares of Intrexon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intrexon's stock price today?

One share of Intrexon stock can currently be purchased for approximately $12.84.

How big of a company is Intrexon?

Intrexon has a market capitalization of $1.63 billion and generates $190.93 million in revenue each year. The biotechnology company earns $-186,610,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Intrexon employs 935 workers across the globe.

How can I contact Intrexon?

Intrexon's mailing address is 1750 Kraft Dr Ste 1400, BLACKSBURG, VA 24060-6147, United States. The biotechnology company can be reached via phone at +1-301-5569809 or via email at [email protected]


MarketBeat Community Rating for Intrexon (XON)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intrexon (NYSE:XON) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.50$38.50$38.50$41.00
Price Target Upside: 225.99% upside225.99% upside225.99% upside89.38% upside

Intrexon (NYSE:XON) Consensus Price Target History

Price Target History for Intrexon (NYSE:XON)

Intrexon (NYSE:XON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Northland SecuritiesReiterated RatingBuy$21.00N/AView Rating Details
11/10/2017Bank of AmericaLower Price TargetNeutral$25.00 -> $21.00N/AView Rating Details
11/10/2017Stifel NicolausBoost Price TargetBuy$39.00 -> $57.00N/AView Rating Details
10/6/2017Griffin SecuritiesReiterated RatingBuy$55.00N/AView Rating Details
10/5/2017JMP SecuritiesReiterated RatingOutperform$42.00N/AView Rating Details
3/14/2017WunderlichLower Price TargetBuy$50.00 -> $35.00HighView Rating Details
11/11/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
3/1/2016MizuhoReiterated RatingNeutral$28.00 -> $29.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Intrexon (NYSE:XON) Earnings History and Estimates Chart

Earnings by Quarter for Intrexon (NYSE:XON)

Intrexon (NYSE XON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.32)N/AView Earnings Details
11/9/2017Q3 2017($0.22)($0.20)$55.17 million$46.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.21)($0.16)$57.17 million$54.40 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.22)($0.26)$49.08 million$53.70 millionViewN/AView Earnings Details
3/1/2017Q416($0.23)($0.37)$52.53 million$46.00 millionViewListenView Earnings Details
11/9/2016Q316($0.21)($0.24)$51.70 million$48.99 millionViewListenView Earnings Details
8/9/2016Q216($0.26)($0.42)$53.78 million$52.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.20)($0.55)$46.26 million$43.40 millionViewListenView Earnings Details
2/29/2016Q415($0.18)($0.28)$41.82 million$41.50 millionViewListenView Earnings Details
11/9/2015Q3($0.21)($0.34)$40.84 million$53.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.04)$0.01$55.93 million$44.90 millionViewListenView Earnings Details
5/11/2015Q115($0.12)$0.25$32.90 million$33.80 millionViewListenView Earnings Details
3/2/2015Q414($0.16)$0.18$26.11 million$31.10 millionViewN/AView Earnings Details
11/13/2014Q314($0.16)($0.53)$19.40 million$21.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$9.39 million$11.80 millionViewN/AView Earnings Details
5/7/2014Q1$0.06$0.04$11.25 million$7.90 millionViewN/AView Earnings Details
3/31/2014Q413($0.14)($0.13)$8.38 million$7.10 millionViewN/AView Earnings Details
11/7/2013($0.03)$0.15$9.79 million$6.10 millionViewN/AView Earnings Details
9/19/2013Q2 2013$0.09($0.17)$22.00 million$6.78 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Intrexon (NYSE:XON) Earnings Estimates

2018 EPS Consensus Estimate: ($0.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.24)($0.24)($0.24)
Q4 20181($0.24)($0.24)($0.24)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Intrexon (NYSE:XON)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intrexon (NYSE XON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 56.30%
Institutional Ownership Percentage: 74.86%
Insider Trades by Quarter for Intrexon (NYSE:XON)
Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Intrexon (NYSE XON) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2018Randal J KirkCEOBuy1,000,000$12.50$12,500,000.00View SEC Filing  
11/13/2017Andrew J LastCOOBuy2,000$12.10$24,200.00View SEC Filing  
8/22/2017Robert B ShapiroDirectorBuy2,850$17.50$49,875.0043,157View SEC Filing  
8/14/2017Andrew J LastCOOBuy2,000$19.99$39,980.002,000View SEC Filing  
8/11/2017Dean J MitchellDirectorBuy5,000$18.33$91,650.0018,103View SEC Filing  
8/11/2017Donald P LehrInsiderBuy1,094$18.33$20,053.0228,249View SEC Filing  
8/11/2017Jeffrey Thomas PerezSVPBuy1,000$17.89$17,890.0012,537View SEC Filing  
8/11/2017Randal J KirkCEOBuy132,625$18.85$2,499,981.25View SEC Filing  
12/13/2016Randal J KirkCEOBuy34,606$28.90$1,000,113.40View SEC Filing  
12/12/2016Joel D LiffmanSVPBuy8,500$28.62$243,270.00158,500View SEC Filing  
12/1/2016Fred HassanDirectorBuy6,900$29.02$200,238.006,900View SEC Filing  
8/29/2016Nir NimrodiSVPBuy4,000$26.12$104,480.00View SEC Filing  
5/13/2016Randal J KirkCEOBuy41,830$23.92$1,000,573.60View SEC Filing  
12/11/2015Randal J KirkCEOBuy124,475$29.85$3,715,578.75View SEC Filing  
12/7/2015Randal J KirkCEOBuy237,525$30.69$7,289,642.25View SEC Filing  
12/4/2015Suma KrishnanSVPSell20,900$35.66$745,294.0042,000View SEC Filing  
1/27/2015Randal J KirkCEOBuy555,556$27.00$15,000,012.00View SEC Filing  
5/13/2014Donald LehrInsiderBuy1,850$15.99$29,581.5015,326View SEC Filing  
5/13/2014Randal KirkCEOBuy65,173$15.19$989,977.87View SEC Filing  
5/9/2014Kelly HuangSVPBuy3,200$15.78$50,496.003,200View SEC Filing  
5/9/2014Krish KrishnanCOOBuy20,900$14.21$296,989.0020,900View SEC Filing  
3/27/2014Randal KirkCEOBuy243,001$25.72$6,249,985.72View SEC Filing  
3/4/2014Gregory Ian FrostSVPBuy100,000$25.95$2,595,000.00100,000View SEC Filing  
8/13/2013Jeffrey B KindlerDirectorBuy33,000$16.00$528,000.00View SEC Filing  
8/13/2013Randal J KirkCEOBuy1,887,500$16.00$30,200,000.00View SEC Filing  
8/13/2013Thomas D ReedInsiderBuy1,800$16.00$28,800.00View SEC Filing  
8/13/2013Thomas R KasserSVPBuy5,000$16.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intrexon (NYSE XON) News Headlines

Source:
DateHeadline
Intrexon (XON) Scheduled to Post Earnings on TuesdayIntrexon (XON) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
B.C. creator of non-browning Arctic apple plans aggressive expansion after positive U.S. test runB.C. creator of non-browning Arctic apple plans 'aggressive expansion' after positive U.S. test run
www.msn.com - February 17 at 4:46 PM
Intrexon Corp (XON) Receives Average Recommendation of "Hold" from BrokeragesIntrexon Corp (XON) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 3:30 PM
$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter
www.americanbankingnews.com - February 9 at 6:56 AM
Chesco gene therapy company seeks FDA OK to begin human testing of skin disorder treatment - Philadelphia Business JournalChesco gene therapy company seeks FDA OK to begin human testing of skin disorder treatment - Philadelphia Business Journal
www.bizjournals.com - February 8 at 6:28 AM
-$0.31 Earnings Per Share Expected for Intrexon Corp (XON) This Quarter-$0.31 Earnings Per Share Expected for Intrexon Corp (XON) This Quarter
www.americanbankingnews.com - February 7 at 1:10 AM
Intrexon (XON) Downgraded by ValuEngine to "Strong Sell"Intrexon (XON) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - February 4 at 6:52 AM
Better Buy: Intrexon Corporation vs. Celgene - Motley FoolBetter Buy: Intrexon Corporation vs. Celgene - Motley Fool
www.fool.com - January 28 at 3:27 PM
Better Buy: Intrexon Corporation vs. CelgeneBetter Buy: Intrexon Corporation vs. Celgene
finance.yahoo.com - January 28 at 3:27 PM
Intrexon (XON) Raised to Hold at Zacks Investment ResearchIntrexon (XON) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 22 at 1:36 PM
Intrexon Corp (XON) CEO Randal J. Kirk Buys 1,000,000 SharesIntrexon Corp (XON) CEO Randal J. Kirk Buys 1,000,000 Shares
www.americanbankingnews.com - January 22 at 9:32 AM
Intrexon Corp (XON) Expected to Post Earnings of -$0.31 Per ShareIntrexon Corp (XON) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - January 21 at 5:24 AM
Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters - PR Newswire (press release)Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters - PR Newswire (press release)
www.prnewswire.com - January 20 at 4:15 PM
Intrexon Corp (XON) Receives Average Recommendation of "Hold" from AnalystsIntrexon Corp (XON) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 5:50 PM
Why IBM, GNC Holdings, and Intrexon Slumped TodayWhy IBM, GNC Holdings, and Intrexon Slumped Today
finance.yahoo.com - January 19 at 4:41 PM
Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by UnderwritersIntrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
www.bizjournals.com - January 19 at 12:13 PM
BRIEF-Intrexon Prices Public Offering Of Common StockBRIEF-Intrexon Prices Public Offering Of Common Stock
www.reuters.com - January 17 at 10:33 AM
Intrexon Prices Public Offering of Common StockIntrexon Prices Public Offering of Common Stock
finance.yahoo.com - January 17 at 10:33 AM
Intrexon Announces Proposed Public Offering of Common Stock - PR Newswire (press release)Intrexon Announces Proposed Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - January 16 at 4:18 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Voyager Therapeutics, Cambrex, Emergent BioSolutions ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Voyager Therapeutics, Cambrex, Emergent BioSolutions ... - PR Newswire (press release)
www.prnewswire.com - January 16 at 4:18 PM
Intrexon Announces Proposed Public Offering of Common StockIntrexon Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 16 at 4:18 PM
ANI Pharmaceuticals (ANIP) & Intrexon (XON) Head-To-Head AnalysisANI Pharmaceuticals (ANIP) & Intrexon (XON) Head-To-Head Analysis
www.americanbankingnews.com - January 12 at 3:28 PM
AquaBounty Technologies, Inc. Announces $12 Million Underwritten Public OfferingAquaBounty Technologies, Inc. Announces $12 Million Underwritten Public Offering
finance.yahoo.com - January 12 at 10:38 AM
Form 8-K INTREXON CORP For: Jan 08Form 8-K INTREXON CORP For: Jan 08
www.streetinsider.com - January 9 at 10:30 AM
Intrexon Corp (XON) Expected to Announce Quarterly Sales of $48.79 MillionIntrexon Corp (XON) Expected to Announce Quarterly Sales of $48.79 Million
www.americanbankingnews.com - January 6 at 6:02 AM
Intrexon to Present at the 36th Annual J.P. Morgan Healthcare ConferenceIntrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 10:33 AM
Intrexons ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8
finance.yahoo.com - January 4 at 10:33 AM
Intrexon Corp (XON) Expected to Announce Earnings of -$0.31 Per ShareIntrexon Corp (XON) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - January 4 at 9:54 AM
Intrexon Corporation Annual CEO Letter - PR Newswire (press release)Intrexon Corporation Annual CEO Letter - PR Newswire (press release)
www.prnewswire.com - January 3 at 4:22 PM
A Cash Infusion from the Boss Props Up Intrexon – For NowA Cash Infusion from the Boss Props Up Intrexon – For Now
www.barrons.com - January 3 at 4:22 PM
A Cash Infusion from the Boss Props Up Intrexon -- For NowA Cash Infusion from the Boss Props Up Intrexon -- For Now
finance.yahoo.com - January 3 at 4:22 PM
Intrexon Corporation Annual CEO LetterIntrexon Corporation Annual CEO Letter
finance.yahoo.com - January 2 at 10:27 AM
Intrexon (XON) Stock Rating Lowered by ValuEngineIntrexon (XON) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 31 at 11:04 PM
Reviewing Intrexon (XON) and The CompetitionReviewing Intrexon (XON) and The Competition
www.americanbankingnews.com - December 28 at 12:16 AM
ETFs with exposure to Intrexon Corp. : December 27, 2017ETFs with exposure to Intrexon Corp. : December 27, 2017
finance.yahoo.com - December 27 at 1:38 PM
Intrexon Corp. :XON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Intrexon Corp. :XON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 10:48 AM
Intrexon Corp (XON) Receives Consensus Recommendation of "Hold" from AnalystsIntrexon Corp (XON) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 25 at 3:54 PM
Contrasting Intrexon (XON) and The CompetitionContrasting Intrexon (XON) and The Competition
www.americanbankingnews.com - December 23 at 1:12 PM
ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare ConferenceZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 4:23 PM
-$0.31 Earnings Per Share Expected for Intrexon Corporation (XON) This Quarter-$0.31 Earnings Per Share Expected for Intrexon Corporation (XON) This Quarter
www.americanbankingnews.com - December 18 at 7:20 PM
ETFs with exposure to Intrexon Corp. : December 14, 2017ETFs with exposure to Intrexon Corp. : December 14, 2017
finance.yahoo.com - December 14 at 4:49 PM
Intrexon Corporation (XON) Major Shareholder Purchases $2,100,000.21 in StockIntrexon Corporation (XON) Major Shareholder Purchases $2,100,000.21 in Stock
www.americanbankingnews.com - December 13 at 8:58 PM
Fibrocell Announces Closing of $10.5 Million Underwritten Public OfferingFibrocell Announces Closing of $10.5 Million Underwritten Public Offering
globenewswire.com - December 11 at 4:27 PM
Head-To-Head Review: Intrexon (XON) vs. Its PeersHead-To-Head Review: Intrexon (XON) vs. Its Peers
www.americanbankingnews.com - December 11 at 1:36 PM
Contrasting Intrexon (XON) and Its PeersContrasting Intrexon (XON) and Its Peers
www.americanbankingnews.com - December 9 at 8:04 AM
Financial Survey: Intrexon (XON) versus Its CompetitorsFinancial Survey: Intrexon (XON) versus Its Competitors
www.americanbankingnews.com - December 9 at 1:22 AM
Critical Analysis: Intrexon (XON) versus The CompetitionCritical Analysis: Intrexon (XON) versus The Competition
www.americanbankingnews.com - December 8 at 5:14 PM
Chester County gene therapy company seeking $10.5M from public stock saleChester County gene therapy company seeking $10.5M from public stock sale
www.bizjournals.com - December 8 at 4:17 PM
Intrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 MillionIntrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 Million
www.americanbankingnews.com - December 2 at 6:00 AM
Head to Head Analysis: Intrexon (XON) and Codexis (CDXS)Head to Head Analysis: Intrexon (XON) and Codexis (CDXS)
www.americanbankingnews.com - December 1 at 11:42 PM

SEC Filings

Intrexon (NYSE:XON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intrexon (NYSE:XON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intrexon (NYSE XON) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.